RECRUITING

Biologic Association Between Metabolic Magnetic Resonance-positron Emission Tomograph (MR-PET) and Tissue Measures of Glycolysis in Brain Tumors of Infiltrating Glioblastoma Cells

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this project is to validate a new combined MRI and PET imaging technique as a biomarker or measure of glycolysis in brain tumors. To accomplish this, the investigators propose obtaining image-guided measures of tissue pH and biopsied tissue in tumor areas selected for bulk resection surgery. Investigators will then correlate the imaging measurements with pH, RNA expression, protein expression, and bioenergetics measurements of key glycolytic enzymes.

Official Title

Biologic Association Between Metabolic MR-PET and Tissue Measures of Glycolysis in Brain Tumors Visualization, Quantitation, and Targeting of Infiltrating Glioblastoma Cells with PH Sensitive Amine Chemical Exchange Saturation Transfer Magnetic Resonance Imaging-KL2TR001882

Quick Facts

Study Start:2023-09-06
Study Completion:2028-09-30
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06059690

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Age \> 18
  2. * Patients with newly diagnosed or recurrent glioblastoma clinically indicated for resective surgery
  1. * Patients who cannot obtain an MRI or FDG PET scan with contrast
  2. * Those with ferromagnetic implanted devices that might produce a safety hazard (e.g. infusion pumps, pace makers, aneurysm clips, etc.) will be excluded from the study along with subjects with severe claustrophobia or who have severely compromised renal function (GFR \< 30).

Contacts and Locations

Study Contact

Raksha Nagaraj
CONTACT
310-794-8995
RNagaraj@mednet.ucla.edu
Saima Chaabane
CONTACT
310-794-8995
schaabane@mednet.ucla.edu

Principal Investigator

Benjamin Ellingson, PhD
PRINCIPAL_INVESTIGATOR
University of California at Los Angeles

Study Locations (Sites)

University of California at Los Angeles
Los Angeles, California, 90095-1406
United States

Collaborators and Investigators

Sponsor: Jonsson Comprehensive Cancer Center

  • Benjamin Ellingson, PhD, PRINCIPAL_INVESTIGATOR, University of California at Los Angeles

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-09-06
Study Completion Date2028-09-30

Study Record Updates

Study Start Date2023-09-06
Study Completion Date2028-09-30

Terms related to this study

Additional Relevant MeSH Terms

  • Glioblastoma Multiforme
  • Glycolytic Index
  • Epidermal Growth Factor Receptor